Live Vaccines Pose Risks with Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses immune response. Avoid live vaccines during treatment and for at least 4-6 weeks after the last dose, as they can cause uncontrolled infection in immunocompromised patients.[1][2]
Examples include:
- MMR (measles, mumps, rubella)
- Varicella (chickenpox)
- Oral polio
- Yellow fever
- Live nasal flu vaccine (FluMist)
- Rotavirus
- Shingrix's live predecessor (Zostavax; Shingrix is inactivated and safe)
Inactivated Vaccines Are Generally Safe
Non-live vaccines, like most COVID-19 shots (Pfizer, Moderna), inactivated flu, Tdap, and pneumococcal, can be given without issue. Discuss timing with your doctor to optimize response.[1][3]
Why the Live Vaccine Restriction?
Cosentyx reduces immune cells, risking dissemination of weakened live viruses. No fatal cases reported specifically with Cosentyx, but biologics like it carry black-box warnings for this.[2]
Timing and Planning Around Dosing
- Start live vaccines 4+ weeks before Cosentyx if possible.
- Post-treatment: Wait until immune recovery (often 4-6 weeks; test if unsure).
- Update all non-live vaccines before starting.[1]
Special Cases for Travelers or Kids
Travelers to yellow fever zones need waivers or pre-treatment vaccination. For children on Cosentyx (approved for ages 6+ in some indications), same rules apply—no live vaccines.[3]
Doctor's Role and Exceptions
No absolute exceptions without specialist approval. Rheumatologists or dermatologists check titers and advise; immunocompromise level varies by dose/duration.[2]
Sources
[1] Cosentyx Prescribing Information (Novartis)
[2] FDA Label for Secukinumab
[3] CDC Guidelines on Immunization and Biologics